KEY TAKEAWAYS
- The phase III trial aimed to determine whether reducing olaparib dosage in recurrent OC impacts PFS.
- The result demonstrated that nearly half of the patients tolerated first-line olaparib with dose reduction, offering physicians flexibility in managing side effects without sacrificing survival benefits.
While PARP inhibitors work well for platinum-sensitive recurrent ovarian cancer(ROC) maintenance, real-world data on how dose adjustments affect survival is lacking, despite SOLO2 suggesting no impact.
So, for a study, researchers aimed to determine whether reducing olaparib dosage in recurrent OC impacts PFS.
The study focused on BRCA 1/2 mutated ROC patients undergoing olaparib treatment from 2019 to 2022 following complete or partial response to platinum-based chemotherapy. All patients commenced with the recommended daily dose of 600 mg.
They were categorized into three groups based on the extent of dose reductions: no reduction (group 1), 1 dose reduction level (group 2), and 2 dose reduction levels (group 3). Progression-free survival (PFS) was assessed for patients without recurrence in the initial 12 weeks.
Of the 81 identified patients, (39.5%) (32) experienced at least one dose reduction, while (54.3%) (44) had no dose modification. Initiating maintenance treatment within 40 days from the last chemotherapy cycle was associated with a slightly lower risk of dose reduction (15/42, 35.7%) vs. (22/39, 56.4%), (P= 0.062).
No significant difference in progression-free survival (PFS) was observed between patients with at least one dose reduction and those without (29 vs. 30 months; log-rank P= 0.74). Median PFS analysis across the three groups also showed similar results (29 vs. 30 vs. 20 months in groups 1, 2, and 3, respectively; P= 0.89).
The result demonstrated that nearly half of the patients tolerated first-line olaparib with dose reduction, offering physicians flexibility in managing side effects without sacrificing survival benefits.
Source: https://ijgc.bmj.com/content/33/Suppl_3/A319.abstract
Clinical Trial: https://clinicaltrials.gov/study/NCT01874353
Boccia SM, Culcasi C, Sassu CM, Guida F, Apostol AI, Vertechy L, Ferrandina G, Fagotti A, Scambia G, Marchetti C. Olaparib Dose Reduction in Platinum-Sensitive Ovarian Cancer Recurrence: Real-World Data.
